Immatics NV (IMTX)
9.50
+0.07
(+0.74%)
USD |
NASDAQ |
Sep 02, 16:00
9.50
0.00 (0.00%)
After-Hours: 20:00
Immatics Research and Development Expense (Annual) : 199.58M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 199.58M |
| December 31, 2024 | 152.93M |
| December 31, 2023 | 125.55M |
| December 31, 2022 | 109.98M |
| Date | Value |
|---|---|
| December 31, 2021 | 101.48M |
| December 31, 2020 | 74.73M |
| December 31, 2019 | 43.37M |
| December 31, 2018 | 37.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| MediGene AG | -- |
| InflaRx NV | 29.03M |
| BioNTech SE | 2.376B |
| Moderna, Inc. | 2.917B |
| Intellia Therapeutics, Inc. | 379.09M |